Skip to nav Skip to content

Clinical Trial Search

306 Clinical Trials Found

Clinical Trial 21117

A Phase 1 Multicenter Study Evaluating the Safety and Efficacy of ALLO-316 Following ALLO-647 Containing Conditioning Regimen in Subjects with Advanced or Metastatic Clear Cell Renal Cell Carcinoma (ccRCC)
Disease Site: Kidney
PI: Chahoud, Jad

Clinical Trial 20827

An Open-Label, Multi-Center Phase I/IIa Study Evaluating the Safety and Clinical Activity of Neoantigen Reactive T cells in Patients with Advanced Non-Small Cell Lung Cancer (CHIRON)
Disease Site: Lung, Non small cell lung cancer
PI: Creelan, Benjamin

Clinical Trial 21078

A Phase 2 Study of ALX148 in Combination with Pembrolizumab and chemotherapy in Patients with Advanced Head and Neck Squamous Cell Carcinoma (ASPEN-04)
Disease Site: Larynx, Lip, Oral Cavity and Pharynx
PI: Chung, Christine

Clinical Trial 21158

Disease Site: Lung
PI: Gray, Jhanelle

Clinical Trial 20274

A Phase II/III Randomized Study of Maintenance Nivolumab versus Observation in Patients with Locally Advanced, Intermediate Risk HPV Positive OPCA
Disease Site: Lip, Oral Cavity and Pharynx
PI: Kirtane, Kedar

Clinical Trial 21731

A Phase II Trial of Olaparib in Combination with Pembrolizumab for Advanced Uveal Melanoma
Disease Site: Melanoma, skin
PI: Khushalani, Nikhil

Clinical Trial 20854

Exercise to Boost Response to Checkpoint Blockade Immunotherapy
Disease Site: Melanoma, skin, Other Skin
PI: Kanetsky, Peter

Clinical Trial 21247

A Randomized Open-Label, Phase 3 Study to Evaluate Imetelstat (GRN163L) Versus Best Available Therapy (BAT) in Patients with Intermediate-2 or High-risk Myelofibrosis (MF) Relapsed / Refractory (R/R) to Janus Kinase (JAK)-Inhibitor
Disease Site: Myeloid and Monocytic Leukemia
PI: Komrokji, Rami

Clinical Trial 21213

A Single-Arm, Open-Label Phase 1b Study of Hyper-CVAD + Calaspargase pegol in Young Adults with Newly Diagnosed Acute Lymphoblastic Leukemia
Disease Site: Lymphoid Leukemia
PI: Shah, Bijal

Clinical Trial 21721

A Randomized Double-Blind Trial of Abatacept Extended Dosing Versus Abatacept Short-Term Dosing for Graft Versus Host Disease Prophylaxis: "ABA3"
Disease Site: Unknown Sites
PI: Pidala, Joseph

Clinical Trial 21749

Phase 1/2, Open-Label, Dose Escalation and Dose Expansion Study of TransCon TLR7/8 Agonist Alone or in Combination with Pembrolizumab in Participants with Locally Advanced or Metastatic Solid Tumor Malignancies
Disease Site: Cervix, Other Female Genital
PI: Avila, Monica

Clinical Trial 21755

Disease Site: Kidney
PI: Chahoud, Jad